Reuters logo
1 年前
BRIEF-Morphosys, Galapagos start first-in-patient dosing of IL-17C antibody MOR106 in atopic dermatitis
2016年9月29日 / 凌晨5点36分 / 1 年前

BRIEF-Morphosys, Galapagos start first-in-patient dosing of IL-17C antibody MOR106 in atopic dermatitis

Sept 29 (Reuters) - Morphosys Ag

* Says Morphosys and Galapagos start first-in-patient dosing of IL-17C antibody MOR106 in atopic dermatitis

* Says favorable safety results shown in healthy volunteers receiving single ascending doses (SAD) in study to date Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below